Vitafoods India V COMPENDIUM

Published by : PHARMA CLICK

Vitafoods India 2025 set to propel nutraceutical industry growth and sustainability

OUR BUREAU, MUMBAI

INDIA's leading B2B events organiser, Informa Markets in India, is set to host the third edition of Vitafoods India from 5th to 7th February 2025 at Pavilion 1-2, Jio World Convention Center, Mumbai. The event will bring together leaders, influencers, and decision-makers from the nutraceutical, functional food, and dietary supplement industries, showcasing a dynamic representation of the sector.

With India's nutraceutical market projected to grow from USD 4 billion in 2020 to USD 18 billion by 2025, with a CAGR of 13.6% expected from 2025 to 2030, the event will serve as a hub for distributors, procurement managers, product development experts, regulatory affairs professionals, and R&D specialists.

This year, Vitafoods India will host 136 domestic and 23 international exhibitors, along with over 19 educational sessions with more than 35 expert speakers who will share insights into the industry's future. The event is expected to attract over 8,000 visitors, reinforcing its role as a premier networking and knowledge-sharing platform for the nutraceutical ecosystem.

CONTINUED ON p2▶

News AT A GLANCE

FSSAI could adopt customised GMP standards for...

Page No. 6

Sustainability, Technology and Innovation Trans...

Page No. 12

India to become global leader in nutraceuticals by...

Page No. 16

Challenges in Developing Certified Organic Supp...

Page No. 29

USFDA will no longer allow for use of FD&C Red No. 3 in food and ingested drugs

OUR BUREAU, MUMBAI



USFDA will no longer allow for the use of FD&C Red No. 3, also referred to as Red Dye No. 3, Red Dye 3, and erythrosine, is a synthetic food dye that gives certain foods and drinks a bright, cherry-red color, and is found in certain candy, cakes and cupcakes, cookies, frozen desserts, and frostings and icings, and ingested drugs.

On January 15, 2025, the FDA issued an order to revoke these authorizations. Manufacturers who use FD&C Red No. 3 in food and ingested drugs will have until January 15, 2027 or January 18, 2028, respectively, to reformulate their products. Consumers could see FD&C Red No. 3 as an ingredient in a food or drug product on the market past the effective date in the order if that product was manufactured before the effective date.

The FDA is revoking the authorization for the use of FD&C Red No. 3 based on the Delaney Clause of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The Delaney Clause, enacted in 1960 as part of the Color Additives Amendment to the FD&C Act, prohibits FDA authorization of a food additive or color additive if it has been found to induce cancer in humans or animals.

The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats. Studies in other animals or in humans did not show the same effect and there is no evidence showing FD&C Red No. 3 causes cancer in humans.

Under the FD&C Act (Chapter VII, section 721), color additives, including FD&C Red No. 3 are subject to FDA approval before they may be used in food, drugs, or cosmetics, or in medical devices that come into direct contact with the bodies of people or animals for a significant period of time.

Color additives, including FD&C Red No. 3, require pre-market review and approval by the FDA. The law requires evidence that a color additive is safe under its intended conditions of use before it may be added to foods.

In the case of color additives, manufacturers submit data and information to the FDA as a petition requesting approval of the intended use. The FDA evaluates the petition, and other existing data and information, and if the data available demonstrates that the substance is safe under the proposed conditions of use, the agency issues a regulation authorizing the use of the color additive. When evaluating the safety of a new color additive or a new use for a listed color additive, the FDA considers factors, including likely amount of consumption, intended use, the manufacturing process, and its physical and chemical properties, among others.

When the FDA approves the use of a color additive, the regulations specify the products in which it can be used, any maximum amounts allowed to be used, its identity and specifications, and whether it must be certified by the FDA. In cases where data demonstrates that a color additive intended for ingestion can induce cancer in human or animal based on appropriate tests, the Delaney Clause directs the FDA to find such uses of the color additive unsafe.

Under the FDA's food labeling regulations, certified colors must be declared in the statement of ingredients on food labels by "FD&C Red No. 3" or without the "FD&C" prefix or the term "No."– "FD&C Red 3" or "Red 3".

Other countries allow the use of FD&C Red No. 3 under a different name, such as in Canada and Europe under the name erythrosine.

Dr Sanjay Agrawal files patent application for new anti-aging formulation

LAXMI YADAV, MUMBAI

WITH an aim to enhance physical, functional, and aesthetic well-being among individuals while extending their lifespans, Dr Sanjay Agrawal, Scientific Advisor of Alkomex GBN Pharma Group, has filed a patent application for an anti-aging formulation with the Indian Patent Office, New Delhi.

The formulation, designed to address aging at a cellular level, has the potential to significantly improve skin health, boost energy levels, and enhance overall vitality. With targeted benefits and innovative ingredients, it is poised to make a lasting impact in the fight against age-related decline, said Dr Agrawal, a distinguished pharmaceutical consultant and inventor with 35 years of experience in research.

Aging is a natural, irreversible process that begins in early adulthood, leading to gradual declines in the functionality of body cells, tissues, and organs. While chronological aging is inevitable, biological and psychological aging differ significantly from one individual to another, influenced by intrinsic and extrinsic factors such as hormonal changes, stress, and lifestyle, he added.

Anti-aging medicine, a revolutionary scientific discipline, is redefining how we approach the aging process. It strives to improve physical, functional, and aesthetic well-being while prolonging lifespans by emphasizing cutting-edge technology, early detection, prevention, and reversal of age-related dysfunctions, he stated.

The American Academy of Anti-Aging Medicine (A4M) emphasizes the importance of lifestyle changes, including staying active, eating nutritious foods, managing stress, and avoiding harmful habits, as cornerstones of healthy aging. Together, these innovations and habits hold the potential to reduce age-related diseases, allowing individuals to live healthier, longer lives.

For over 35 years, Dr. Agrawal has been at the forefront of innovation. He has 42 patents for original formulas, many of which have found successful commercialization. Providing services including new product development, marketing strategies, and regulatory support, Dr. Agrawal's company places a strong emphasis on quality, dependability, integrity, and cooperation.